Form 4: Blueprint Medicines CSO Percy H. Carter Sells Shares to Cover Tax Obligations

Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp, sold 2,436 shares of common stock on June 3, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On June 3, 2024, Percy H. Carter, the Chief Scientific Officer of Blueprint Medicines Corp, sold 2,436 shares of the company's common stock.
• The sale was executed at a price of $106.43 per share.
• This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Carter directly owns 45,895 shares of Blueprint Medicines Corp.
• The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't reflect a change in the executive's confidence in the company.

Management Comments

• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares may have a minor, temporary impact on the stock price, but it is unlikely to significantly affect long-term shareholder value.

Key Dates